IRD Opus Genetics
- 1.075
- -0.025-2.27%
Opus Genetics News
CCORF Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10
Opus Genetics: Promising Future With Key Data Readouts and Strong Financial Position Justify Buy Rating
Opus Genetics Reinstated With a Buy at H.C. Wainwright
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $9
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Cuts Target Price to $9
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Opus Genetics (IRD)
Ocuphire Pharma Is Maintained at Buy by Canaccord Genuity
Ocuphire Pharma Analyst Ratings
CCORF Maintains Ocuphire Pharma(OCUP.US) With Buy Rating, Cuts Target Price to $10
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX) and Ocuphire Pharma (OCUP)
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Chimerix (CMRX) and Mersana Therapeutics (MRSN)
Ocuphire Pharma Analyst Ratings
Ocuphire Pharma Analyst Ratings
Buy Rating Affirmed: Ocuphire Pharma's APX3330 Shows Promise for Diabetic Retinopathy and Pipeline Progress
Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Ocuphire Pharma (OCUP) and Vertex Pharmaceuticals (VRTX)
Ocuphire Pharma Analyst Ratings
Ocuphire Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Merus (MRUS) and Eli Lilly & Co (LLY)
Buy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy Treatment
Buy Rating Affirmed for Ocuphire Pharma on Promising Clinical Advancements and Strategic Partnerships
Analysis
Price Target
No Data
No Data